SCHEMBL10044899

SCHEMBL10044899

CCCOC(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 1/20 0.47
PABPC1 P11940 1/20 0.47
LMNA P02545 1/20 0.43
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
GABRA4 P48169 1/20 0.42
GABRE P78334 1/20 0.42
GABRA6 Q16445 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10044903 0.93 ALDH1A1 (0.51) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL1685962 0.90 ALDH1A1 (0.65) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL39437 0.84 EGFR (0.48) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL12009978 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL10044900 0.81 CA12 (0.48) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL889415 0.79 EGFR (0.51) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL16079758 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL2574422 0.78 EGFR (0.47) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL19114816 0.78 MEN1 (0.60) ALDH1A1KDM4EMEN1KMT2ANPC1
SCHEMBL7598991 0.78 ALDH1A1 (0.68) ALDH1A1KDM4EMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590949-B1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2015-11-25 EP disclosed
EP-2590949-B1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2015-11-25 EP disclosed
US-8871936-B2 Method for manufacturing of quinoline-3-carboxamides ACTIVE BIOTECH AB (SE) 2014-10-28 US disclosed
US-8871936-B2 Method for manufacturing of quinoline-3-carboxamides ACTIVE BIOTECH AB (SE) 2014-10-28 US disclosed
US-8871936-B2 Method for manufacturing of quinoline-3-carboxamides ACTIVE BIOTECH AB (SE) 2014-10-28 US disclosed
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2013-05-02 US disclosed
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2013-05-02 US disclosed
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2013-05-02 US disclosed
WO-2012004338-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ADH1A, ADH5, ADH1C ALDH1A1 7/4885KDM4E 1451/4885MEN1 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.